Fennec Pharmaceuticals Statistics
Share Statistics
Fennec Pharmaceuticals has 27.6M
shares outstanding. The number of shares has increased by 1%
in one year.
| Shares Outstanding | 27.6M |
| Shares Change (YoY) | 1% |
| Shares Change (QoQ) | 0.61% |
| Owned by Institutions (%) | 58.63% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 15,446 |
| FTD / Avg. Volume | 18.48% |
Short Selling Information
The latest short interest is 1.45M, so 5.27% of the outstanding
shares have been sold short.
| Short Interest | 1.45M |
| Short % of Shares Out | 5.27% |
| Short % of Float | 7.67% |
| Short Ratio (days to cover) | 33.59 |
Valuation Ratios
The PE ratio is -395.64 and the forward
PE ratio is 6.34.
Fennec Pharmaceuticals's PEG ratio is
4.06.
| PE Ratio | -395.64 |
| Forward PE | 6.34 |
| PS Ratio | 3.63 |
| Forward PS | 1.1 |
| PB Ratio | -31.33 |
| P/FCF Ratio | 6.39 |
| PEG Ratio | 4.06 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Fennec Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.38,
with a Debt / Equity ratio of -3.51.
| Current Ratio | 6.38 |
| Quick Ratio | 6.22 |
| Debt / Equity | -3.51 |
| Debt / EBITDA | 5.37 |
| Debt / FCF | 0.72 |
| Interest Coverage | 0.63 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,485,562.5 |
| Profits Per Employee | $-13,625 |
| Employee Count | 32 |
| Asset Turnover | 1.06 |
| Inventory Turnover | 3 |
Taxes
| Income Tax | 365K |
| Effective Tax Rate | -514.08% |
Stock Price Statistics
The stock price has increased by -8.45% in the
last 52 weeks. The beta is 0.32, so Fennec Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.32 |
| 52-Week Price Change | -8.45% |
| 50-Day Moving Average | 5.99 |
| 200-Day Moving Average | 5.7 |
| Relative Strength Index (RSI) | 57.7 |
| Average Volume (20 Days) | 83,588 |
Income Statement
In the last 12 months, Fennec Pharmaceuticals had revenue of 47.54M
and earned -436K
in profits. Earnings per share was -0.02.
| Revenue | 47.54M |
| Gross Profit | 44.35M |
| Operating Income | 2.57M |
| Net Income | -436K |
| EBITDA | 3.6M |
| EBIT | 2.57M |
| Earnings Per Share (EPS) | -0.02 |
Full Income StatementBalance Sheet
The company has 26.63M in cash and 19.34M in
debt, giving a net cash position of 7.29M.
| Cash & Cash Equivalents | 26.63M |
| Total Debt | 19.34M |
| Net Cash | 7.29M |
| Retained Earnings | -219.68M |
| Total Assets | 44.95M |
| Working Capital | 37.2M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 26.98M
and capital expenditures 0, giving a free cash flow of 26.98M.
| Operating Cash Flow | 26.98M |
| Capital Expenditures | n/a |
| Free Cash Flow | 26.98M |
| FCF Per Share | 0.99 |
Full Cash Flow StatementMargins
Gross margin is 93.3%, with operating and profit margins of 5.4% and -0.92%.
| Gross Margin | 93.3% |
| Operating Margin | 5.4% |
| Pretax Margin | -0.15% |
| Profit Margin | -0.92% |
| EBITDA Margin | 7.57% |
| EBIT Margin | 5.4% |
| FCF Margin | 56.75% |
